A cohort study of vincristine-induced peripheral neuropathy in children.
10.7499/j.issn.1008-8830.2212032
- Author:
Chuang LI
1
;
Jiao JIN
1
;
Jing HUANG
1
;
Xiao-Yan YANG
1
;
Yan LI
1
;
Yong-Yan YAN
1
;
Can YANG
1
Author Information
1. Department of Pediatrics, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
- Publication Type:Journal Article
- Keywords:
Acute lymphoblastic leukemia;
Child;
Peripheral neuropathy;
Vincristine
- MeSH:
Child;
Humans;
Antineoplastic Agents, Phytogenic/adverse effects*;
Cohort Studies;
Peripheral Nervous System Diseases/diagnosis*;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Vincristine/adverse effects*;
Infant;
Child, Preschool;
Adolescent
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(5):470-475
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the characteristics of vincristine-induced peripheral neuropathy (VIPN) in children with acute lymphoblastic leukemia (ALL) and the factors influencing the development of VIPN.
METHODS:The children with ALL, aged 1-18 years, who were treated with CCCG-ALL2015 or CCCG-ALL2020 regimen in the Affiliated Hospital of Guizhou Medical University from January 2018 to February 2022 were enrolled as subjects. According to the influence of age on risk, the children were divided into 1-10 years group with 91 children and >10 years group with 29 children. VIPN was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (5th edition), and the incidence rate, severity, and type of VIPN were compared between different groups.
RESULTS:A total of 120 children were enrolled in this study, among whom 56 (46.7%) developed VIPN. The >10 years group had a significantly higher incidence rate of VIPN than the 1-10 years group (69% vs 40%, P<0.05). Among the 56 children with VIPN, 12 (21%) had grade 3 VIPN or above, and 44 (79%) had grade 2 VIPN. There were 77 cases of autonomic nerve symptoms (59.7%), 42 cases of peripheral nerve injury (32.5%), and 10 cases of cranial nerve injury (7.8%). There were no significant differences in the severity and type of VIPN between the groups with different ages, sexes, degrees of risk, or treatment regimens (P>0.05). The results of binary logistic regression analysis showed that age is the influencing factor for the occurrence of VIPN (P>0.05).
CONCLUSIONS:There is a relatively high incidence rate of VIPN in children with ALL, with the highest incidence rate of autonomic nervous symptoms. The incidence of VIP in children over 10 years old is relatively high.
